Medically reviewed by Jessica Swirble, PharmDLast updated on March 31, 2025
Drug Information| | |
Dosage and Administration:
Strattera is primarily used to treat adults with attention-deficit hyperactivity disorder (ADHD). It works by increasing the levels of norepinephrine and dopamine in the brain.
Important Information:
Warnings:
Last updated on March 31, 2025
Medically reviewed by&ll:&ll: Reviewed by a member of the Science-Applied Compileable Review Board.
|
Aatomoxetine is an atypical type of selective norepinephrine reuptake inhibitor (SSRI). It is primarily used to treat attention-deficit hyperactivity disorder (ADHD) and mixed personality disorder. It works by increasing the levels of norepinephrine in the brain.
Atypical SSRIs are not FDA-approved for use in ADHD treatment.
 
Strattera note: As of November 2023, drug manufacturer Eli Lilly and Company discontinued all strengths of Strattera from the marketplace. Strattera generic, atomoxetine, is sold in multiple formats, such as tablet and liquid form. Currently, Strattera tablet is available in a 56-capsule pack in the UK, the United States, the European Union and Canada. Eli Lilly and Company does not hone its purpose as a generic or marketing authorizations retrieval – it is solely responsible for this product’s sales.
Strattera is a selective norepinephrine reuptake inhibitor (SNRI) medication primarily used to treat attention-deficit/hyper-hydrexate (AD/HFA) eating- disorder and major depressive disorder. It works by increasing the levels of norepinephrine in the brain, which helps regulate appetite and increases the amount of calories absorbed, leading to improved energy levels and mental alertness.
is a branded prescription medication that represents Eli Lilly’s partner pharmaceutical company. It contains the active ingredient atomoxetine, which is a type of selective norepinephrine reuptake inhibitor (SNRI) medication. Strattera is manufactured by Eli Lilly under the brand name Adderall and is sold in multiple forms, such as tablets, capsules and oral suspensions. Strattera’s patent on Adderall expired in 2023 and is now available under various brand names, including Adderall, Dexedrine, Famotidine, Juvastatin, Mevacor, Nusimod, Pristiq, Teva, and Venlafaxine. Strattera is not regulated by the FDA and is not intended for use by patients with diminished potency of norepinephrine.
is a liquid formulation available. It’s available in the following oral suspension formulations:
are indicated for the treatment of ADHD, which is a core symptom of ADHD. Strattera Tablets is manufactured by Eli Lilly in the brand name Adderall. Strattera is sold under various brand names, including Avanafil, Strattera, Tatomoxetine, and Strattera. Strattera’s patent on Adderall expired in 2023 and is now available under various brand names, including Allyn.
is indicated for the management of obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder ( social anxiety disorder with a strong risk of developing agoraphobia, or excessive fear of authority or peers). It is also indicated for patients with bulimia, premenstrual dysphoric disorder, and symptoms of major depressive disorder. Strattera Tablets is not approved for use in children under 18 years of age in the UK.
is indicated for the management of panic disorder, premenstrual dysphoric disorder, and symptoms of menopause. It is also indicated for the treatment of symptoms of irritability associated with menopausal symptoms.
Strattera Oral Suspension is also indicated to treat symptoms of gastro-intestinal ulcer, bleeding disorder, inflammatory bowel disorder, and perforation of the stomach. It is also indicated for the treatment of symptoms of depression. Strattera Tablets is not approved for the treatment of children under the age of 18 years.
is an atomoxetine drug. Strattera Tablets are manufactured by Eli Lilly in the brand name Adderall. Strattera is sold under various brand names, including Adderall, Dexedrine, Famotidine, Juvastatin, Mevacor, Nusimod, Pristiq, Teva, and Venlafaxine. Strattera’s patent on Adderall expired in 2023 and is now available under various brand names, including Adderall.
The following patient information sheet provides general information about Strattera, including its uses, benefits, side effects, and precautions. It is important to consult with a healthcare professional before using Strattera, especially if you have any underlying medical conditions or are taking other medications. Your healthcare provider may be able to adjust your Strattera dosage based on your individual needs and health history.
If you have any questions about using Strattera, ask your doctor or pharmacist. Your doctor or pharmacist can provide more information.
This information is for educational purposes only and does not constitute medical advice. The content is not intended to diagnose or treat any medical ailment or disease. Before using Strattera, tell your doctor or pharmacist if you are taking, have recently taken, or have recently used any other medication or have been taking other substances. Your doctor or pharmacist may also be able to provide more information.
If you have any questions about using Strattera, talk to your doctor or pharmacist. You may need to adjust your dosage based on your individual needs and medical history.
The following information does not identify all patients or healthcare providers. You should not be considered as a health provider or patient unless you have discussed it with your doctor or pharmacist. Your health conditions should be discussed with your doctor or pharmacist, and you should be notified by phone if you have any questions.
Patients who are allergic to Strattera or any of its ingredients should not take this medication. The active ingredient in Strattera is atomoxetine. Patients with allergic reactions to Strattera should avoid using this medication if they have any allergies.
Stroke is a leading cause of disability in the United States, and there are currently no effective treatments for stroke. Strattera is not considered to be a drug of any kind. Strattera is not approved for the treatment of ADHD and other symptoms of ADHD in children. Strattera is only approved for the treatment of ADHD in children with ADHD. Strattera is not approved for use by adults. Strattera may be prescribed in children under the age of 18 years. Strattera is not approved for the treatment of ADHD in adults. Strattera is not approved for the treatment of depression and is not approved for use by adults. Strattera is not approved for the treatment of children with ADHD, and Strattera is not approved for use in children under the age of 18 years. Strattera is not approved for use by women.Strattera may be used for purposes not approved by the Food and Drug Administration. You are encouraged to report negative side effects to the FDA at www.fda.gov/EN/CONTACT/report-your-drug-prescribing/.
To the Editor:
To learn more about all the drug and non-drug uses, talk to your doctor or pharmacist.
FDA Prescribing Information:ADHD is a disorder in which a person's brain cells become overactive and unable to process sensory information. They experience difficulties with concentration, memory, and attention. These difficulties can be related to the overactive, underactive, or hyperactive brain cells that are responsible for the problem. Attention is impaired because of the overactive or hyperactive cells that are responsible for making and processing sensory information.
The use of Strattera has not been studied in children. Strattera is not approved for use by children.
ADHD is a neurodevelopmental disorder that causes difficulties in thinking, behavior, or other aspects of life. It can occur in children and in older adults.
A new study suggests that ADHD medication is a potential treatment option for adults with ADHD. In a new study, researchers have now shown that Strattera is a potential treatment for adults with ADHD who are taking the medication. They suggest that Strattera may be a viable medication option for people with ADHD who have trouble paying attention to their ADHD symptoms. A new study has also shown that Strattera is a potential treatment option for patients with ADHD who are not paying attention to their symptoms. Strattera is available in both capsule and tablet form, but it is important to note that Strattera has a longer half-life, which means it may take longer for it to start working. In this study, the researchers reviewed more than 3,500 patients who had ADHD symptoms that were not due to ADHD symptoms. They compared the average time to notice improvement for each patient and compared the time to notice improvement for each patient who was started on Strattera. They concluded that patients with ADHD who are started on Strattera are able to notice a significant improvement in their ADHD symptoms after a six-week course of treatment. The new study was published today in the Journal of Clinical Psychiatry.
ADHD is a common and well-known psychiatric condition in which patients with ADHD experience difficulty paying attention to their symptoms. This can cause distress, difficulty concentrating, and reduced interest in activities.
In this study, researchers looked at a group of adults with ADHD who were treated with Strattera and found that Strattera was able to improve their ADHD symptoms.
The study was published in the Journal of Clinical Psychiatry.
The findings suggest that Strattera is a potential treatment option for people with ADHD who have trouble paying attention to their symptoms. The new study also suggests that Strattera may be a viable medication option for people with ADHD who have been prescribed Strattera.
In a new study, researchers have shown that Strattera is a potential treatment option for adults with ADHD who are taking the medication. In a new study, researchers have shown that Strattera is a potential treatment option for adults with ADHD who have been prescribed Strattera. They suggest that Strattera may be a viable medication option for people with ADHD who have been prescribed Strattera.
A new study has also been published in the Journal of Clinical Psychiatry. The researchers compared the average time to notice improvement for each patient and compared the time to notice improvement for each patient who was started on Strattera. They found that patients with ADHD who are started on Strattera are able to notice a significant improvement in their ADHD symptoms after a six-week course of treatment.
A new study has been published today in the Journal of Clinical PsychiatryADHD is a common and well-known psychiatric condition in which patients with ADHD have difficulty paying attention to their symptoms. While Strattera is a potential treatment option for people with ADHD who have been prescribed Strattera, there are several other treatments available for ADHD that may be less expensive than Strattera. There are also other medications that may be less expensive than Strattera.
In a new study, researchers have also shown that Strattera is a potential treatment option for adults with ADHD who are taking the medication. In a new study, researchers have shown that Strattera is a potential treatment option for adults with ADHD who have been taking the medication.
Stade de France Pharmacy